Mirum Pharmaceuticals (STU:08D) Short-Term Debt: €0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:08D Mirum Pharmaceuticals Inc STU:08D
52 GF Score
Price €91.94
GF Value €72.19
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Short-Term Debt?

Mirum Pharmaceuticals STU:08D -5.61% 52 Short-Term Debt is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:08D with a GF Score™ of 52/100 and a GF Value™ of €72.19 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Mirum Pharmaceuticals's Short-Term Debt for the quarter that ended in Mar. 2026 was €0.0 Mil.

Mirum Pharmaceuticals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Mirum Pharmaceuticals Short-Term Debt Related Terms

Mirum Pharmaceuticals Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Short-Term Debt Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:08D
52GF Score
Mirum Pharmaceuticals Inc STU:08D
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.0 Mil mean?
Mirum Pharmaceuticals (STU:08D) has a Short-Term Debt of €0.0 Mil as of Mar. 2026.
Is Mirum Pharmaceuticals' Short-Term Debt too high?
Mirum Pharmaceuticals' current Short-Term Debt is €0.0 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Short-Term Debt compare to COGT and RYTM?
Mirum Pharmaceuticals' Short-Term Debt of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Mirum Pharmaceuticals's current Short-Term Debt is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Modestly Overvalued. The stock's GF Value™ is €72.19, compared to a current price of €91.94 — trading 27.4% above its estimated fair value. The current Short-Term Debt is €0.0 Mil. Mirum Pharmaceuticals' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Short-Term Debt is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €91.94 is trading 27.4% above its estimated GF Value™ of €72.19. GuruFocus considers Mirum Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for STU:08D:

  • Short-Term Debt: €0.0 Mil
  • GF Value™: €72.19 vs. price of €91.94 (27.4% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
52GF Score

Get the complete analysis for STU:08D

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€91.94
Price
€72.19
GF Value